Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Apellis Pharmaceuticals Inc
1JKCurrent price
24.78 EUR
-1.27 EUR (-4.88%)
Last closed
28.06 USD
Company
www.apellis.com
ISIN
US03753U1060
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
3 679 544 832 USD
Yield for 12 month
-46.50 %
1Y
3Y
5Y
10Y
15Y
1JK
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
46.22 USDP/E ratio
–Dividend Yield
–Current Year
+396 591 000 USD
Last Year
+75 422 000 USD
Current Quarter
+176 571 000 USD
Last Quarter
+199 685 000 USD
Current Year
+336 377 000 USD
Last Year
+69 786 000 USD
Current Quarter
+143 014 000 USD
Last Quarter
+176 136 000 USD
Key Figures 1JK
1 year
3 years
5 years
10 years
EBITDA
-221 507 008 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-16.23 %
PEG Ratio
–
Return On Equity TTM
-106.56 %
Wall Street Target Price
46.22 USD
Revenue TTM
715 216 000 USD
Book Value
1.94 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
78.3 %
Dividend Yield
–
Gross Profit TTM
69 786 000 USD
Earnings per share
-2.03 USD
Diluted Eps TTM
-2.03 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-34.97 %
Dividend Analytics 1JK
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 1JK
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 1JK
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
5.3241
Price Sales TTM
5.1447
Enterprise Value EBITDA
-12.123
Price Book MRQ
15.7484
Financials 1JK
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 1JK
For 52 weeks
24.34 USD
73.8 USD
50 Day MA
31.02 USD
Shares Short Prior Month
15 260 698
200 Day MA
44.02 USD
Short Ratio
6.81
Shares Short
21 088 064
Short Percent
23.91 %
BeatStart